Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Olatec Therapeutics logo — Leading the Development of Specific NLRP3 Antagonists,​ Medi...

Olatec Therapeutics

Leading the Development of Specific NLRP3 Antagonists,​ Mediator of Innate Inflammatory Response

Founded 2003 United States New York, United States 15 employees Grant Total: $102.26M Biopharma, Biotechnology +2

General Information

Company Name Olatec Therapeutics
Founded Year 2003
Location United States New York, United States +1
Employees 15
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Grant
Social

Get notified when Olatec Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Olatec Therapeutics

Olatec Therapeutics is a privately held biopharmaceutical company founded in 2003 that is leading the development of specific NLRP3 antagonists, which are the mediators of the innate inflammatory response. The company is focused on developing a platform of safe, oral NLRP3 antagonist therapeutics to address a wide range of acute and chronic inflammatory diseases, including arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma, and breast cancers, among others. Olatec's lead compound, dapansutrile (lab code: OLT1177®), selectively targets NLRP3 to inhibit the production of pro-inflammatory cytokines IL 1B and IL 18, thus showing promise in treating these conditions. The company's last investment, a grant investment, was secured on 10 March 2023 from the Michael J. Fox Foundation. Olatec's drug development team, with over 10 years of experience, has unparalleled expertise in inflammation and immunology and includes international thought leaders. Olatec operates in the United States and Europe, with offices in New York and the Netherlands. With its innovative approach and focus on addressing unmet medical needs in the field of inflammatory diseases, Olatec Therapeutics has the potential to make a significant impact in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries.

Taxonomy: biopharmaceutical company, NLRP3 antagonist, IL-1 mediated diseases, inflammatory diseases, drug development, dapansutrile, inflammation treatment, innate immune system, pro-inflammatory cytokines, management expertise, immunology, United States operations, European operations, New York office, Netherlands office

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
10 Mar 2023
Series A •••••• 3
Investor Investor Investor
23 Feb 2023
Series A •••••• - 01 Aug 2019
Series A •••••• - 18 Oct 2018
Series A •••••• - 29 Sep 2015

View All 10 Funding Rounds

Olatec Therapeutics Alternatives & Competitors

Olatec Therapeutics vs
Azome Therapeutics
Azome Therapeutics

Developing selective NLRP3 inflammasome inhibitors for severe inflammatory diseases

Seed
3 employees
Biopharma, Biotechnology
Olatec Therapeutics vs
Ventyx Biosciences
Ventyx Biosciences United States

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapie...

Post Ipo Equity
242 employees
Biopharma, Biotechnology
Olatec Therapeutics vs
13therapeutics
13therapeutics

13therapeutics is a research and drug development company identifying and characterizing novel anti-...

Grant
4 employees
Health Care

FAQ About Olatec Therapeutics

Leading the Development of Specific NLRP3 Antagonists,​ Mediator of Innate Inflammatory Response
Olatec Therapeutics was founded in 2003.
Olatec Therapeutics is headquartered in New York, United States.
Olatec Therapeutics operates in the following industries: Biopharma, Biotechnology, Health Care, Pharmaceutical.
Olatec Therapeutics has approximately 15 employees.
Olatec Therapeutics has completed 10 funding rounds, raising a total of $102.26M. The latest funding stage is Grant.
Top alternatives and competitors to Olatec Therapeutics include Azome Therapeutics, Ventyx Biosciences, 13therapeutics, Resolvyx Pharmaceuticals, Peptinnovate Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Olatec Therapeutics and Azome Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Olatec Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy